Safety data for the PI3Kδ inhibitor umbralisib for lymphoid malignancies - 101793

Spotlight
Video

Safety data for the PI3Kδ inhibitor umbralisib for lymphoid malignancies

VJHemOnc has 1143 videos Subscribe Here

Loading........
Description: In this interview, Susan O’Brien, MD, of the University of California, Irvine, CA, talks to us about the next-generation PI3Kδ inhibitor umbralisib for patients with relapsed/refractory lymphoid malignancies. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Prof. O’Brien discusses the large-scale safety data presented. She highlights the importance of this data, and compares umbralisib to idelalisib and duvelisib.
Shared By : VJHemOnc
Posted on : 01/17/18
Added : 6 months ago
Category : Lymphoma